enGene Therapeutics Inc ENGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
enGene to Host KOL Webinar on October 15, 2026
-
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
-
enGene to Participate in Upcoming Investor Conferences
-
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
-
EnGene Reports Positive Preliminary Data for Bladder-Cancer Drug
Trading Information
- Previous Close Price
- $1.58
- Day Range
- $1.59–1.72
- 52-Week Range
- $1.40–12.25
- Bid/Ask
- $1.67 / $1.73
- Shares Outstanding
- 67.02M
- Market Cap
- $111.92M
- Volume/Avg
- 364 / 741,797
Key Statistics
- Price/Earnings (Normalized)
- 1.21
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 82
- Website
- https://www.engene.com
Valuation
|
Metric
|
ENGN
|
|---|---|
Price/Earnings (Normalized) | 1.21 |
Price/Book Value | 0.49 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ENGN
Financial Strength
|
Metric
|
ENGN
|
|---|---|
Quick Ratio | 9.82 |
Current Ratio | 10.21 |
Interest Coverage | −44.81 |
Quick Ratio
ENGN
Profitability
|
Metric
|
ENGN
|
|---|---|
Return on Assets (Normalized) | −40.21% |
Return on Equity (Normalized) | −49.58% |
Return on Invested Capital (Normalized) | −45.92% |
Return on Assets
ENGN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^R@#Q& | LOCK|Kdql | $130B | |||
| Moderna Inc
MRNA
| LOCK|NC$@&w< | LOCK|?! | $97B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|j?#>Dw | LOCK|<Zp& | $83B | |||
| argenx SE ADR
ARGX
| LOCK|q&H^VXk | LOCK|s$d | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<Jr^?RP | LOCK|?^ | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^gFnW@ | LOCK|zgln | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|yQkd%&@^ | LOCK|P>@Mj | $28B | |||
| Incyte Corp
INCY
| LOCK|Q<B$$L | LOCK|%Q | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|Px<#QV& | LOCK|^w? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|p&&lNl | LOCK|nGw | $14B |
United States